Aldosterone signaling in atrial fibrillation another piece in the puzzle of atrial remodeling.

o trial fibrillation (AF) is a rapidly evolving epidemic repesenting a multifactorial, dynamic disorder with different nderlying substrates and serious health consequences (1). growing body of evidence indicates that, apart from the riggers, AF development and perpetuation depends on the lectrical and structural remodeling of the atria (2,3). urrently, the role of the renin-angiotensin-aldosterone ystem in AF is under intensive investigation (4), whereas uch of the current interest regarding pharmacologic therpy has shifted to nonchannel-blocking drugs with pleioropic properties including agents interfering in the reninngiotensin-aldosterone system (2,4,5).